Table 2.
MiR-219a silencing atagomiR blocks the protective role of Sev on cardiac dysfunction.
| Index | Time | Sev + I/R + AntagomiR-Mock group | Sev + I/R + AntagomiR-219a group |
|---|---|---|---|
| HR (beat/min) | T0 | 159.67 ± 11.41 | 154.90 ± 10.41 |
| T4 | 129.16 ± 13.55 | 106.36 ± 15.12 | |
| LVDP (mmHg) | T0 | 114.72 ± 9.63 | 104.16 ± 6.97 |
| T4 | 68.83 ± 5.32 | 47.32 ± 4.13 | |
| LVEDP (mmHg) | T0 | 7.86 ± 0.75 | 7.94 ± 1.28 |
| T4 | 29.84 ± 3.02 | 36.57 ± 3.10 | |
| dp/dtmax(+)(mmHg/s) | T0 | 2994.01 ± 197.61 | 2919.65 ± 199.27 |
| T4 | 1617.53 ± 138.64 | 1313.44 ± 114.28 | |
| dp/dtmax(-)(mmHg/s) | T0 | 2303.91 ± 213.69 | 2316.88 ± 216.22 |
| T4 | 1010.42 ± 103.77 | 654.47 ± 34.87 |
Note: Sev, Sevoflurane; IRI, ischemia/reperfusion injury; HR, heart rate; LVEDP, left ventricular end-diastolic pressure; LVDP, left ventricular developmental pressure; dp/dtmax (+), maximum rate of rise of left ventricular pressure; dp/dtmax (-), maximum rate of decline of the left ventricular pressure.